Supplementary material

Appendix 1. The search string

Medline via Ovid

1.exp AMG 145/

2.exp Evolocumab/

3.exp REGN727/

4.exp SAR236553/

5.exp Alirocumab/

6.exp RN316/

7.exp Bococizumab/

8.exp RG7652/

9.exp LY3015014/

10.exp ALN-PCSS/

11.exp PCSK9 antibodies/

12.exp anti-PCSK9/

13.exp Clinical Trial/

14.exp Randomized Controlled Trial/

15.exp Controlled Clinical Trial/

16.exp Random Allocation/

17.1 OR 2 OR 3 OR 4 OR 5 OR 6 OR7 OR 8 OR 9 OR 10 OR 11 OR 12

18.13 OR 14 OR 15 OR 16

19.17 AND 18

20. limit 19 to (humans)

Pubmed

"amg145"[Title/Abstract]) OR "Evolocumab"[Title/Abstract]) OR "REGN727"[Title/Abstract]) OR "SAR236553"[Title/Abstract]) OR "Alirocumab"[Title/Abstract]) OR "RN316"[Title/ Abstract]) OR "bococizumab"[Title/Abstract]) OR "RG7652"[Title/Abstract]) OR "LY3015014" [Title/Abstract]) OR "ALN-PCSSC"[Title/Abstract]) OR "PCSK9 antibodies"[Title/Abstract]) OR "anti-PCSK9"[Title/ Abstract]) AND randomized controlled trial[Publication Type]) AND "humans"[MeSH Terms]

Supplemental Table 1. Quality assessment of included studies using the Jadad scale

Studies	Representation of randomization	Appropriateness of method for randomization	Representation of double blinding	Appropriateness of method for double blinding	Representation of withdrawals	Total Score
RUTHERFORD	1	1	1	1	1	5
Stein EA 2012	1	1	1	1	1	5
DESCARTES	1	1	1	1	1	5
GAUSS-2	1	1	1	0	1	5
RUTHERFORD-2	1	1	1	0	1	4
TESLA Part B	1	1	1	0	1	4
ODYSSEY COMBO II	1	1	1	0	1	4
GLAGOV	1	1	1	0	1	4
Kastelein 2016	1	1	1	0	1	4
EQUATOR	1	1	1	0	1	4

Representation of randomization:0, not randomized or inappropriate method of randomization; 1, the study was described as randomized.
Appropriateness of method for randomization: 0, no information about the method of randomization;1, the method of randomization was described and it was appropriate.
Representation of double blinding: 0, no blind or inappropriate method of blinding; 1, the study was described as double blinding.
Appropriateness of method for double blinding: 0, no information about the method of double blinding;1, the method of double blinding was described and it was appropriate.
Withdrawals and dropouts:0, not describe the follow-up; 1, a description of withdrawals and dropouts.

Supplementary Figure 1. Evaluation of risk of bias in the studies.



Supplementary Figure 2. Pooled analysis for hs-CRP stratified by PCSK9-mAb types.



WMD= weighted mean difference, CI = confidence interval, PCSK9-mAb= proprotein convertase subtilisin/kexin type 9 monoclonal antibody, hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 3. Pooled analysis for hs-CRP stratified by treatment durations.



WMD=weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 4. Pooled analysis for hs-CRP stratified by participant characteristics



WMD= weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein, FH=familial hypercholesterolemia, non-FH= non-familial hypercholesterolemia

Supplementary Figure 5. Pooled analysis for hs-CRP stratified by of treatment methods.



WMD=weighted mean difference, CI = confidence interval, hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 6. Sensitivity analyses of hs-CRP.



hs-CRP=hypersensitive C-reactive protein

Supplementary Figure 7. Funnel Plots of included studies



Supplementary Figure 8. Meta-regression of baseline age (A), sex (B) and percent change of LDL-C (C).



LDL-C=low density lipoprotein cholesterol